seperator

About Ethris

seperator

 

seperator

About Ethris

seperator

 

A SHORT INTRODUCTION

Based in Planegg just outside Munich, Germany, Ethris was founded by Dr. Carsten Rudolph and Prof. Christian Plank to establish messenger RNA (mRNA) as a new drug modality. As an mRNA pioneer, we are applying our unique, proprietary SNIM® RNA platform and our proprietary lipidoid nanoparticle (LNP) formulation and delivery platform to provide highly versatile, multi-route, multi-cargo delivery options that drive a range of drug candidates through proof-of-concept and into the clinic. Our goal is to develop therapeutics for the treatment of respiratory viral infections and rare pulmonary diseases while also developing the next-generation of mRNA vaccines that are mutation-agnostic, multivalent and mucosal, which we call the “Triple-M” concept.

We maintain a first-mover advantage through our differentiated nebulization technology for inhaled delivery of mRNA-containing nanoparticles directly to the upper and lower respiratory tract. By maintaining the potential to expand into a broad range of indications with our platforms we can address important unmet medical needs worldwide.

Learn more about our technology.

LEARN MORE